-
January 13, 2025Umecrine Cognition attends the 43rd Annual JP Morgan Healthcare ConferenceSTOCKHOLM – January 13, 2024. Umecrine Cognition today announced that the company will attend the 43rd Annual J.P. Morgan Healthcare Conference in...
-
December 19, 2024Umecrine Cognition raises MSEK 23,8 to the ongoing clinical Phase 1b/2 study of golexanoloneSTOCKHOLM – December 19, 2024. Umecrine Cognition today announced that the company has raised SEK 23,8 million through a convertible loan with...
-
November 18, 2024Umecrine Cognition presents positive interim data from ongoing Phase 1b/2a study with golexanolone at the AASLD Liver Meeting in San DiegoSTOCKHOLM – November 18, 2024. Umecrine Cognition today announces that the company will present late-breaking data from a recent interim analysis...
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.